Kitty Moores

3.5k total citations · 1 hit paper
34 papers, 3.0k citations indexed

About

Kitty Moores is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Kitty Moores has authored 34 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 13 papers in Oncology and 10 papers in Immunology. Recurrent topics in Kitty Moores's work include Chemokine receptors and signaling (12 papers), Immune Cell Function and Interaction (6 papers) and Cell Adhesion Molecules Research (5 papers). Kitty Moores is often cited by papers focused on Chemokine receptors and signaling (12 papers), Immune Cell Function and Interaction (6 papers) and Cell Adhesion Molecules Research (5 papers). Kitty Moores collaborates with scholars based in United Kingdom, United States and Canada. Kitty Moores's co-authors include J E Merritt, Colin H. Macphee, Gayle A. Chapman, Trevor J. Hallam, T J Rink, Albert Jaxa‐Chamiec, Christopher D. Benham, B. K. Leigh, Ron Jacob and Michael P.A. Davies and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Neuroscience.

In The Last Decade

Kitty Moores

34 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SK&F 96365, a novel inhibitor of receptor-mediated calcium entry

1990 712 citations J E Merritt, Christopher D. Benham et al. Biochemical Journal profile →

Peers

Countries citing papers authored by Kitty Moores

Since Specialization

Citations

This map shows the geographic impact of Kitty Moores's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kitty Moores with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kitty Moores more than expected).

Fields of papers citing papers by Kitty Moores

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kitty Moores. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kitty Moores. The network helps show where Kitty Moores may publish in the future.

Co-authorship network of co-authors of Kitty Moores

This figure shows the co-authorship network connecting the top 25 collaborators of Kitty Moores. A scholar is included among the top collaborators of Kitty Moores based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kitty Moores. Kitty Moores is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In silicoandin vitroevaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization 2015 ·Nucleic Acids Research ·Piotr J. Kamola, Jeremy Kitson, (unknown), Klio Maratou, (unknown), Aliza A. Panjwani, (unknown), (unknown), Kitty Moores, Emma Koppe, William E. Wixted, Paul A. Wilson, Nigel J. Gooderham, Timothy W. Gant, Kenneth L. Clark, Stephen Hughes, Mark R. Edbrooke, Joel D. Parry	81
2	In vivo activity of an azole series of CCR2 antagonists 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Nicola Bevan, (unknown), Amanda Emmons, Peter J. Gough, Claudette Mookherjee, Kitty Moores, Simon Peace, (unknown), (unknown), Steve P. Watson, Mara Zippoli	1
3	Identification of a sulfonamide series of CCR2 antagonists 2010 ·Bioorganic & Medicinal Chemistry Letters ·Simon Peace, (unknown), (unknown), (unknown), Kitty Moores, (unknown), Steve P. Watson, (unknown), Mara Zippoli, Claudette Mookherjee, Robert J. Ife	19
4	The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2 2003 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Jackie C. Bloomer, Murray J. B. Brown, Hung‐Yuan Cheng, Beverley Hammond, Deirdre M. B. Hickey, Robert J. Ife, Colin A. Leach, Vahn A. Lewis, Colin H. Macphee, Kevin J. Milliner, Kitty Moores, Ivan L. Pinto, Stephen A. Smith, Ian Stansfield, Steven J. Stanway, Maxine Taylor, Colin J. Theobald	100
5	Fractalkine Is Expressed by Smooth Muscle Cells in Response to IFN-γ and TNF-α and Is Modulated by Metalloproteinase Activity 2002 ·The Journal of Immunology ·Andreas Ludwig, Theo A. Berkhout, Kitty Moores, Pieter H.E. Groot, Gayle A. Chapman	124
6	Sema7A is a Potent Monocyte Stimulator 2002 ·Scandinavian Journal of Immunology ·Steve Holmes, Angela M. Downs, Andrew Fosberry, Philip D. Hayes, David Michalovich, (unknown), Kitty Moores, James M. Fox, Keith C. Deen, Gary Pettman, Trevor Wattam, Claire E. Lewis	131
7	PPARγ Is Not a Critical Mediator of Primary Monocyte Differentiation or Foam Cell Formation 2002 ·Biochemical and Biophysical Research Communications ·Lisa Patel, Steven J. Charlton, Ian C. B. Marshall, Gary B.T. Moore, (unknown), Kitty Moores, John C. Clapham, (unknown), Stephen A. Smith, Colin H. Macphee	21
8	CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound 2000 ·Bioorganic & Medicinal Chemistry Letters ·Ian T. Forbes, David G. Cooper, (unknown), Deirdre M. B. Hickey, Robert J. Ife, (unknown), Martin L. Stockley, Theo A. Berkhout, (unknown), Pieter H.E. Groot, Kitty Moores	41
9	N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2 2000 ·Bioorganic & Medicinal Chemistry Letters ·Helen Boyd, (unknown), (unknown), Deirdre M. B. Hickey, Robert J. Ife, Colin A. Leach, Colin H. Macphee, Kevin J. Milliner, Kitty Moores, Ivan L. Pinto, Rod A. Porter, (unknown), Stephen A. Smith, Ian Stansfield, David G. Tew, Colin J. Theobald, (unknown)	24
10	Selective binding of the truncated form of the chemokine CKβ8 (25–99) to CC chemokine receptor 1 (CCR1) 2000 ·Biochemical Pharmacology ·Theo A. Berkhout, (unknown), Paula González, (unknown), Kitty Moores, Colin H. Macphee, John R. White, Pieter H.E. Groot	12
11	The role of fractalkine in the recruitment of monocytes to the endothelium 2000 ·European Journal of Pharmacology ·Gayle A. Chapman, Kitty Moores, (unknown), Theo A. Berkhout, Lisa Patel, (unknown), Colin H. Macphee, Brian R. Stewart	81
12	Anti-atherosclerotic effect of SB-244323, a lipoprotein associated phospholipase A2 inhibitor, in WHHL rabbits 2000 ·Atherosclerosis ·G. Martin Benson, David C. Grimsditch, (unknown), Kitty Moores, Helen Boyd, David G. Tew, Deirdre M. B. Hickey, Robert J. Ife, Keith E. Suckling, Colin H. Macphee	12
13	Identification of a Truncated Form of the CC Chemokine CKβ-8 Demonstrating Greatly Enhanced Biological Activity 1998 ·The Journal of Immunology ·Colin H. Macphee, Edward R. Appelbaum, Kyung Johanson, Kitty Moores, (unknown), (unknown), Theo A. Berkhout, Mary Brawner, Pieter H.E. Groot, Kevin O’Donnell, Daniel J. O’Shannessy, (unknown), John R. White	23
14	Expression, purification and characterization of a human serine-dependent phospholipase A2 with high specificity for oxidized phospholipids and platelet activating factor 1998 ·Biochemical Journal ·(unknown), Christopher Southan, (unknown), (unknown), (unknown), Kitty Moores, (unknown), (unknown)	26
15	Cloning, in Vitro Expression, and Functional Characterization of a Novel Human CC Chemokine of the Monocyte Chemotactic Protein (MCP) Family (MCP-4) That Binds and Signals through the CC Chemokine Receptor 2B 1997 ·Journal of Biological Chemistry ·Theo A. Berkhout, Henry M. Sarau, Kitty Moores, John R. White, Nabil A. Elshourbagy, Edward R. Appelbaum, (unknown), (unknown), (unknown), James J. Foley, Dulcie B. Schmidt, (unknown), Dean E. McNulty, (unknown), Kevin O’Donnell, Daniel J. O’Shannessy, Miller O. Scott, Pieter H.E. Groot, Colin H. Macphee	88
16	Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils 1997 ·Journal of Leukocyte Biology ·John R. White, (unknown), Edward Dul, Edward R. Appelbaum, Kevin O’Donnell, Daniel J. O’Shannessy, Mary Brawner, (unknown), John E. Adamou, Nabil A. Elshourbagy, Kate M. Kaiser, James J. Foley, Dulcie B. Schmidt, Kyung Johanson, Colin H. Macphee, Kitty Moores, Dean E. McNulty, Gilbert Scott, Robert P. Schleimer, Henry M. Sarau	135
17	Human neutrophils have a novel purinergic P2-type receptor linked to calcium mobilization 1991 ·Cellular Signalling ·James H. Merritt, Kitty Moores	11
18	Octimibate, a potent non‐prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor 1991 ·British Journal of Pharmacology ·Janet E. Merritt, Trevor J. Hallam, Anthony Brown, (unknown), David G. Cooper, Deirdre M. B. Hickey, Albert Jaxa‐Chamiec, Alberto J. Kaumann, Mary Keen, Eamonn Kelly, (unknown), James A. Lynham, Kitty Moores, Kenneth Murray, John MacDermot, T J Rink	30
19	SK&F 96365, a novel inhibitor of receptor-mediated calcium entry breakdown → 1990 ·Biochemical Journal ·J E Merritt, (unknown), Christopher D. Benham, Trevor J. Hallam, Ron Jacob, Albert Jaxa‐Chamiec, B. K. Leigh, (unknown), Kitty Moores, T J Rink	712
20	The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function 1990 ·British Journal of Pharmacology ·Kenneth Murray, P. England, Trevor J. Hallam, (unknown), Kitty Moores, Martin L. Reeves, Alec W.M. Simpson, T J Rink	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact